Abstract A polypeptide which specifically binds to the γ-chain of the human interleukin-2 receptor and selectively inhibits the binding of the γ-chain of human interleukin-2 receptor to the β-chain of the same is provided. The polypeptide has an activity of blocking the human interleukin-2 response. Also provided are an immunosuppressant containing the polypeptide, a DNA gene coding for the polypeptide, a recombinant DNA having the gene, a transformant having the recombinant DNA, and a method for producing the intended polypeptide by incubating the transformant. The novel polypeptide can be used independently, or with substances capable of inhibiting the binding of interleukin-2 to the interleukin-2 receptor, as a medicine for preventing the rejection of grafts after transplantation and also for curing inflammatory diseases such as allergic diseases and autoimmune diseases.
A polypeptide which (1) is a monoclonal antibody produced by the hybridoma cells of TUGh4 (FERM BP 4642), TUGh5 (FERM BP4643) or AG14 (FERM BP 4648) and (2) has an activity of inhibiting human interleukin 2 triggered responses which result by binding of the γ chain of human interleukin 2 receptor to the β-chain of human interleukin 2 receptor.
Claim 2
Dependent Claim
59 words
A polypeptide which (1) is a monoclonal antibody produced by the hybridoma cells of TUGh4 (FERM BP 4642), TUGh5 (FERM BP4643) or AG14 (FERM BP 4648) and (2) has an activity of inhibiting human interleukin 2 triggered responses which result by binding of the γ chain of human interleukin 2 receptor to the β-chain of human interleukin 2 receptor.
Claim 3
Dependent Claim
71 words
An immunosuppressant composition comprising a carrier and a therapeutically effective amount of a polypeptide which (1) is a monoclonal antibody produced by the hybridoma cells of TUGh4 (FERM BP 4642), TUGh5 (FERM BP4643) or AG14 (FERM BP 4648) and (2) has an activity of inhibiting human interleukin 2 triggered responses which result by binding of the γ chain of human interleukin 2 receptor to the β-chain of human interleukin 2 receptor.
Claim 4
Dependent Claim
71 words
An immunosuppressant composition comprising a carrier and a therapeutically effective amount of a polypeptide which (1) is a monoclonal antibody produced by the hybridoma cells of TUGh4 (FERM BP 4642), TUGh5 (FERM BP4643) or AG14 (FERM BP 4648) and (2) has an activity of inhibiting human interleukin 2 triggered responses which result by binding of the γ chain of human interleukin 2 receptor to the β-chain of human interleukin 2 receptor.